Ladenburg Thalmann Financial Services’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-364
| Closed | – | – | 5568 |
|
|
2018
Q4 | $0 | Sell |
364
-40
| -10% | -$42 | ﹤0.01% | 5579 |
|
|
2018
Q3 | $0 | Sell |
404
-41
| -9% | -$64 | ﹤0.01% | 5599 |
|
|
2018
Q2 | $0 | Hold |
445
| – | – | ﹤0.01% | 5244 |
|
|
2018
Q1 | $0 | Hold |
445
| – | – | ﹤0.01% | 5379 |
|
|
2017
Q4 | $1K | Hold |
445
| – | – | ﹤0.01% | 5005 |
|
|
2017
Q3 | $1K | Sell |
445
-300
| -40% | -$1.01K | ﹤0.01% | 4907 |
|
|
2017
Q2 | $2K | Hold |
745
| – | – | ﹤0.01% | 4686 |
|
|
2017
Q1 | $2K | Buy |
745
+57
| +8% | +$222 | ﹤0.01% | 4656 |
|
|
2016
Q4 | $3K | Sell |
688
-1
| -0.1% | -$4 | ﹤0.01% | 4499 |
|
|
2016
Q3 | $3K | Hold |
689
| – | – | ﹤0.01% | 4431 |
|
|
2016
Q2 | $2K | Hold |
689
| – | – | ﹤0.01% | 4511 |
|
|
2016
Q1 | $3K | Hold |
689
| – | – | ﹤0.01% | 4334 |
|
|
2015
Q4 | $3K | Hold |
689
| – | – | ﹤0.01% | 4319 |
|
|
2015
Q3 | $3K | Sell |
689
-150
| -18% | -$689 | ﹤0.01% | 4219 |
|
|
2015
Q2 | $4K | Sell |
839
-83
| -9% | -$796 | ﹤0.01% | 4201 |
|
|
2015
Q1 | $7K | Buy |
922
+300
| +48% | +$1.49K | ﹤0.01% | 3873 |
|
|
2014
Q4 | $2K | Buy |
+622
| New | +$2.5K | ﹤0.01% | 4153 |
|
Ladenburg Thalmann Financial Services's AST Position: Q1 2019 in Review
Ladenburg Thalmann Financial Services sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 364 shares.
Ladenburg Thalmann Financial Services first reported a position in AST in Q4 2014 and held it in 17 quarters. The position peaked at $7K in Q1 2015. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.
- Ladenburg Thalmann Financial Services reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
- Ladenburg Thalmann Financial Services sold 364 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
- Ladenburg Thalmann Financial Services first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 17 quarters.
- Ladenburg Thalmann Financial Services's Asterias Biotherapeutics Inc. Series A position peaked at $7K in Q1 2015.
- 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.
Based on Ladenburg Thalmann Financial Services's 13F filing for Q1 2019, filed 15 May 2019.